Washington, D.C. - In a recent 10-week, three-dose phase II trial of inflaximab (Remicade), 87.9 percent of the 250 participants achieved PASI 75, while 58 percent achieved PASI 90 at the 10-week mark.
Editorial Advisory Board Insights for Eczema Awareness Month: Raj Chovatiya, MD, PhD
The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis
Derm In The News: September 24-30
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
The Importance of Timing With Live Vaccinations in Pediatric Atopic Dermatitis
Evaluating Efficacy of Trifarotene in Latin American Patients With Acne